CINC News and Press, CinCor Pharma Inc. From 04/19/22

WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) --  CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida. The CinCor management team will participate in one-on-one...

CINC's single asset is CIN-107 targeting hypertension. The company is well-funded after a solid IPO. A number of data catalysts will happen in 2022. For further details see: CinCor: 2022 Data Catalysts Will Derisk The Stock

CinCor Pharma press release (NASDAQ:CINC): Q4 GAAP EPS of -$15.71. Ended 2021 with approximately $136.6 million in cash and cash equivalents. Shares +0.74%. For further details see: CinCor Pharma GAAP EPS of -$15.71

BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer ...

As part of the quarterly initial public offering (IPO) additions, CinCor Pharma (NASDAQ:CINC) will join the Russell 2000 and Russell 3000 Indexes, effective Mar. 18, 2022. In early 2022, the biopharmaceutical company filed to offer 12.1M shares of its common stock at $16/share, for expected g...

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that the Company will be a...

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fo...

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team wi...

Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...

Shares of CinCor Pharma Inc. (NASDAQ:CINC) traded at a new 52-week high today of $28.75. This new high was reached on below average trading volume as 101,000 shares traded hands, while the average 30-day volume is approximately 196,000 shares. CinCor Pharma Inc is a clinical-stage biopha...